In particular, homozygous PAI-1 and high-risk FVL carriers may benefit from prophylactic LMWH and enhanced monitoring, especially in the presence of additional risk factors like obesity or prior obstetric complications. This evidence concerns the gene SERPINE1 and obesity disorder.